ClinicalTrials.gg
Not yet recruitingNCT07644195Updated Jun 12, 2026

Study to Evaluate Safety and Activity of Inhaled TRL1068 in Healthy Volunteers

A Phase 1 interventional study of TRL1068, a human monoclonal antibody in Healthy Volunteer, sponsored by Trellis Bioscience LLC. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Trellis Bioscience LLC · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study in healthy volunteers will provide a basis for evaluation of inhaled TRL1068 as a first in human study, specifically, important safety, tolerability, and pharmacokinetic data.

Read the detailed description

This is a Phase 1, double-blind study to assess the safety and PK of inhaled TRL1068. Healthy subjects aged 18-65, inclusive, will be screened. Subjects who meet all inclusion and no exclusion criteria will be enrolled into the study, assigned to a dose group (DG), and randomized to receive IP.

The single dose (SD) study (Study Part A) will enroll one dose group (DG) of 7 healthy participants (5 active and 2 placebo), with each participant receiving a single inhaled dose of TRL1068 or matching placebo [IP]. This DG will include a sentinel group of two participants (1 active and 1 placebo) who will be dosed at least 24 hours before the remaining five participants (4 active and 1 placebo). The remaining participants in a DG will only be dosed if no clinically significant safety or tolerability concerns are observed in the sentinel group, following review of the blinded safety data from the first two subjects in the DG by the PI and Sponsor. All participants in DG1 will be admitted to a Phase 1 research unit prior to the inhalation of IP on Day 1 and domiciled for 24 hours for observation.

The multiple dose (MD) study (Study Part B) will enroll one DG of 7 healthy participants (5 active and 2 placebo). Participants will receive inhaled doses of TRL1068 or matching placebo every other day for 7 days (on Days 1, 3, 5, and 7).

DGs will be enrolled sequentially with a safety review completed between DGs. A Study Monitoring Committee (SMC) will review all available safety data 48 hours after the last subject in a DG has completed the last dose prior to making a recommendation regarding escalation to the next higher DG.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Trellis Bioscience LLC is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and non-pregnant, non-breast-feeding female subjects at between 18 and 65 years of age, inclusive, and representative of the general population
  2. Normal spirometry at Screening, defined as ≥ 80%
  3. Willing and able to provide written
  4. Availability for the entire duration of the study, and willingness to adhere to protocol requirements
  5. In good health, as determined by lack of abnormalities in health assessments performed at the Screening Visit, as judged by the Principal Investigator (PI) or as delegated by the PI to a physician or nurse practitioner as sub-investigator
  6. Men and women of (WOCBP) must be willing to practice a highly effective method of that may include, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with vasectomized partner, vasectomy, hysterectomy, bilateral tubal ligation, licensed hormonal methods, or intrauterine device (IUD) for 28 days before Screening and for 90 days after Day 1. Men must also refrain from donating sperm from Day 1 and for 90 days after Day 1.

Exclusion criteria

Exclusion Criteria:

  1. Inability to tolerate blood draws or has poor venous access
  2. (BMI) \<18.5 or ≥35 kg/m2
  3. vital sign abnormalities (systolic blood pressure lower than 90 or over 160 mmHg; diastolic blood pressure lower than 50 or over 100 mmHg; or, heart rate less than 45 or over 100 bpm) at the Screening Visit
  4. Clinical diagnosis of acute or chronic viral or bacterial infection with the exception of chronic recurrent herpes simplex infection
  5. with clinically significant findings, including:

    1. Conduction disturbance (complete left or complete right bundle branch block or nonspecific intraventricular conduction disturbance with QRS ≥120 msec, PR interval ≥220 msec, any second- or third-degree atrioventricular block, or prolongation of the corrected according to Fridericia's correction [>450 msec male and >460 msec female])
    2. Significant repolarization (ST-segment or T-wave) abnormality; or
    3. Significant atrial or ventricular arrhythmia; or
    4. Frequent atrial or ventricular ectopy (e.g., frequent premature atrial contractions, 2 premature ventricular contractions in a row); or
    5. ST-elevation consistent with ischemia or evidence of past or evolving myocardial infarction
  6. Presence of any gastrointestinal pathology (e.g., chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g., diarrhea, vomiting), or progressive liver or kidney disease
  7. Significant abnormal safety labs, defined as:

    • Greater than 30% outside of the normal range for any of the following: , white blood cell (WBC) count, count, and blood urea nitrogen
    • (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), direct or indirect bilirubin >2 × the
    • (aPTT) prolongation >1.5 x ULN
    • Renal function based on the, i.e., estimated \< 70 mL/min (Cockcroft-Gault formula using ideal body weight)
    • Hemoglobin ≤ 128 g/L (males) and ≤ 115 g/L (females), and hematocrit ≤ 37% (males) and ≤ 32.0% for females
  8. Positive test results for , (HBsAg), or (HCV) at the Screening Visit
  9. History of significant drug abuse within one year prior to the Screening Visit and/or ongoing
  10. History of significant alcohol abuse within one year prior to the Screening Visit defined as more than fourteen units of alcohol per week (one "unit" is equal to approximately ½ pint [200 mL] of beer, 1 small glass [100 mL] of wine, or 1 measure [25 mL] of spirits)
  11. Positive test for drugs of abuse, ETOH and nicotine (cotinine) at the Screening Visit
  12. Positive serum beta-human chorionic gonadotropin test for pregnancy, pregnant, or nursing women
  13. Unwilling to refrain from donating blood or plasma during the study
  14. Use of any new prescription medication or over-the-counter (OTC) product (including natural food supplements, vitamins, herbs) within 14 days prior to dosing
  15. Receipt of any vaccine or booster within 14 days prior to Day 1 or planned vaccination or booster within 4 weeks after IP administration
  16. Any planned medical intervention or personal event that might interfere with the ability to comply with the study requirements
  17. Is current study site staff paid entirely or partially by the contract for this trial, or staff who are supervised by the PI or sub-PI
  18. Receipt of an product, or participation in another trial involving a marketed or investigational drug within 30 days of Day 1, or 5 half-lives of the investigational drug, whichever is longer
  19. Any other comorbidity or condition that, in the opinion of the Investigator would make the subject unsuitable for the study or unable to comply with the study requirements
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Single Dose

    Randomized 5:2 (TRL1068:placebo) via inhalation. Administered once on Day 1.

    Drug: TRL1068, a human monoclonal antibody

  • Experimental
    Multiple Dose

    Randomized 5:2 (TRL1068:placebo) via inhalation. Administered four times, on Days 1, 3, 5, and 7.

    Drug: TRL1068, a human monoclonal antibody

Interventions

  • The IP will be in a solution for inhalation at a nominal concentration of 20 mg/mL. The IP will be reconstituted with a formulation buffer to 10 mg/mL/PS20 0.055% and dosed at a fixed dose of 60 mg per dose (volume of 6 mL) to full completion. Placebo will be normal saline. This study will use a marketed nebulizer device, the Aerogen Solo™, which is designed to generate an aerosol to achieve effective levels of TRL1068 in distal airways.

06

What researchers measure

Primary outcomes

  1. Incidence of abnormal physical exam findings

    Clinically-significant abnormal physical exam findings will be reviewed

    Time frame: 30 days

  2. Severity of abnormal physical exam findings

    Clinically-significant abnormal physical exam findings will be reviewed. Severity scale used in this trial is Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (https://www.fda.gov/media/73679/download).

    Time frame: 30 days

  3. Incidence of abnormal serum chemistries and hematology

    Clinically-significant abnormal laboratory results findings will be reviewed

    Time frame: 30 days

  4. Severity of abnormal serum chemistries and hematology

    Clinically-significant abnormal laboratory results findings will be reviewed. Severity scale used in this trial is Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (https://www.fda.gov/media/73679/download).

    Time frame: 30 days

  5. Incidence of abnormal vital signs (temperature)

    Clinically-significant abnormal temperatures will be reviewed

    Time frame: 30 days

  6. Severity of abnormal vital signs (temperature)

    Clinically-significant abnormal temperatures will be reviewed

    Time frame: 30 days

  7. Incidence of abnormal vital signs (blood pressure)

    Clinically-significant abnormal blood pressures will be reviewed

    Time frame: 30 days

  8. Severity of abnormal vital signs (blood pressure)

    Clinically-significant abnormal blood pressures will be reviewed

    Time frame: 30 days

  9. Incidence of abnormal vital signs (heart rate)

    Clinically-significant abnormal heart rates will be reviewed

    Time frame: 30 days

  10. Severity of abnormal vital signs (heart rate)

    Clinically-significant abnormal heart rates will be reviewed

    Time frame: 30 days

  11. Incidence and Severity of Adverse Events

    reported AEs will be reviewed

    Time frame: 30 days

  12. Incidence of Serious Adverse Events

    reported SAEs will be reviewed

    Time frame: 30 days

Secondary outcomes

  1. Characterize the pharmacokinetics (PK) of inhaled TRL1068 overall and by DG (Cmax)

    determined by ELISA

    Time frame: 8 days

  2. Characterize the pharmacokinetics (PK) of inhaled TRL1068 overall and by DG (Cmin)

    determined by ELISA

    Time frame: 8 days

  3. Characterize the pharmacokinetics (PK) of inhaled TRL1068 overall and by DG (CL)

    determined by ELISA

    Time frame: 8 days

  4. Characterize the pharmacokinetics (PK) of inhaled TRL1068 overall and by DG (Vss)

    determined by ELISA

    Time frame: 8 days

  5. Characterize the pharmacokinetics (PK) of inhaled TRL1068 overall and by DG (T1/2)

    determined by ELISA

    Time frame: 8 days

  6. Assess the immunogenicity of inhaled TRL1068 as measured by anti-drug antibodies (ADAs)

    Incidence of baseline and IP-emergent ADA (i.e., anti-TRL1068 antibodies) in serum will determined by electrochemiluminescence assay

    Time frame: 30 days

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartEst.
Oct 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07644195
Lead sponsor
Trellis Bioscience LLC
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 12, 2026

Study contacts

Anton (Tony) Leighton, MD
Contact
clinicalstudies@trellisbio.com
650-838-1400
Adriane Kisch-Hancock
Contact
AKisch-Hancock@trellisbio.com
650-838-1400

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TRL1068

Start the discussion